Division of Cardiology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Suite 600, Chicago, IL, 60611, USA.
Diagnostics Division, Abbott Laboratories, 100 Abbott Park Road, CP1-3, Abbott Park, North Chicago, IL, 60064-6094, USA.
Curr Treat Options Oncol. 2021 Apr 17;22(6):46. doi: 10.1007/s11864-021-00845-0.
Improvements in cancer survival have led to the emergence of cardiovascular disease as an important determinant of adverse outcome in survivors. Cancer therapeutics-related cardiac dysfunction is the most well-known form of cardiotoxicity. However, newer cancer therapies bring a broader range of cardiotoxicities. The optimal method to identify patients at risk of these complications is unclear, but circulating biomarkers comprise one possible approach. Troponins and natriuretic peptides have garnered the broadest evidence base for cardiotoxicity risk prediction, but other markers are being investigated. In this review, we explore evidence for circulating biomarkers in cardiotoxicity prediction associated with cancer therapies.
癌症存活率的提高导致心血管疾病成为幸存者不良预后的重要决定因素。癌症治疗相关的心脏功能障碍是最常见的一种心脏毒性。然而，更新的癌症疗法带来了更广泛的心脏毒性。确定这些并发症高危患者的最佳方法尚不清楚，但循环生物标志物是一种可能的方法。肌钙蛋白和利钠肽在心脏毒性风险预测方面获得了最广泛的证据基础，但其他标志物也在研究中。在这篇综述中，我们探讨了与癌症治疗相关的心脏毒性预测中循环生物标志物的证据。
